What is Raremark?
Raremark operates at the intersection of patient advocacy and biopharmaceutical innovation. The company constructs research networks comprising rare disease patients and their families, offering biopharmaceutical firms unique access to anonymized and aggregated patient data. This data is crucial for advancing clinical development and expediting the delivery of therapies to market. Raremark's vision is to contribute to a future where all rare diseases are treatable. The platform employs machine learning and behavioral science to engage and retain patients, thereby enhancing health literacy and fostering informed participation in medical research. The growing knowledge base of patient experiences, built over time through the collective contributions of its community members, significantly enhances the platform's value.
How much funding has Raremark raised?
Raremark has raised a total of $6.9M across 3 funding rounds:
Private Equity
$1M
Other Financing Round
$2.1M
Series A
$3.8M
Private Equity (2016): $1M, investors not publicly disclosed
Other Financing Round (2018): $2.1M, investors not publicly disclosed
Series A (2018): $3.8M supported by Ananda Ventures, Albion Capital Group, Oltre Venture, and Cass Entrepreneurship Fund
Key Investors in Raremark
Albion Capital Group
Albion Capital Group is an investor that has participated in Raremark's funding rounds. Their involvement suggests a focus on companies with strong growth potential in the healthcare or technology sectors.
Cass Entrepreneurship Fund
The Cass Entrepreneurship Fund, a venture capital fund based at Cass Business School, invests in high-potential, revenue-generating businesses. Their participation in Raremark indicates support for innovative companies within the early-stage growth sector.
Ananda Ventures
Ananda Ventures is an investor in Raremark, contributing to the company's capital raises. Their specific investment focus is not detailed but their participation highlights support for Raremark's mission.
What's next for Raremark?
With major enterprise-level funding and a recent strategic investment, Raremark is well-positioned for significant expansion and enhanced data acquisition capabilities. The company's focus on leveraging patient data for biopharmaceutical advancement aligns with industry trends prioritizing real-world evidence. Future growth will likely involve scaling its research networks, further developing its machine learning and behavioral science tools for patient engagement, and forging deeper partnerships with pharmaceutical companies. This strategic financing will enable Raremark to solidify its position as a key enabler of rare disease research and development, potentially accelerating the path to new treatments.
See full Raremark company page
